002287 奇正藏药
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入405,2530.56%2,416,0122,337,9702,045,1522,044,789
减:营业总成本315,928-2.30%1,850,6731,858,5031,628,6741,555,973
    其中:营业成本65,117-12.54%409,473418,375323,315324,140
               财务费用(181)-101.26%35,38753,86750,22939,922
               资产减值损失148-83.21%(982)(1,179)(1,401)(2,454)
公允价值变动收益16,055-14.00%66,367105,13737,074(3,429)
投资收益(1,734)-47.99%1,724(4,822)28,780(33,652)
    其中:对联营企业和合营企业的投资收益(1,857)17.34%(7,902)(6,466)1,888(54,907)
营业利润109,08010.44%768,625657,025646,383521,541
利润总额109,03722.47%739,842646,244644,413519,202
减:所得税费用15,0728.17%92,36864,87565,23549,560
净利润93,96525.13%647,474581,370579,178469,643
减:非控股权益(1,214)107.45%(951)(911)(2,021)(2,900)
股东净利润95,17925.77%648,425582,281581,199472,542

市场价值指针
每股收益 (元) *0.16817.96%1.1931.0981.0970.892
每股派息 (元) *----0.6300.6000.4800.390
每股净资产 (元) *8.81220.31%8.6487.4076.7646.039
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容